Advicenne Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
ALDVI
- Share Price
-
$2.48
- (As of Wednesday Closing)
Advicenne General Information
Description
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Contact Information
- 262, Rue du Faubourg Saint Honoré
- 75008 Paris
- France
Advicenne Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.48 | $2.54 | $2.45 - $6.26 | $25.7M | 10.1M | 18.3K | -$1.09 |
Advicenne Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 51,025 | 54,681 | 103,522 | 95,291 |
| Revenue | 2,510 | 2,520 | 3,179 | 2,434 |
| EBITDA | (9,097) | (10,139) | (14,357) | (16,012) |
| Net Income | (10,873) | (12,060) | (14,692) | (16,923) |
| Total Assets | 11,631 | 15,291 | 21,377 | 29,524 |
| Total Debt | 20,355 | 20,113 | 14,196 | 16,970 |
Advicenne Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Advicenne Comparisons
Industry
Financing
Details
000000
000000
Advicenne Competitors (12)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genocea Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 0000000000. | |
| 00000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 0000000000. | |
| 0000000 | Corporation | Beijing, China | 0000 | 00000 | 000000 - 000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Burnaby, Canada | 000 | 000.00 | 000000000 | 000.00 |
| 000 00000000 | Corporation | Cambridge, MA | 000 | 000.00 | 00000000 | 000.00 |
Advicenne Patents
Advicenne Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2553424-T3 | Pharmaceutical composition that includes citrate and bicarbonate salts, and their use for the treatment of cystinuria | Active | 18-Nov-2010 | 0000000000 | |
| US-9636304-B2 | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | Active | 18-Nov-2010 | 0000000000 | 0 |
| AU-2011331019-A1 | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | Active | 18-Nov-2010 | 0000000000 | |
| AU-2011331019-B2 | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | Active | 18-Nov-2010 | 0000000000 | |
| CA-2816660-A1 | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | Active | 18-Nov-2010 | A61K9/2072 |
Advicenne Executive Team (13)
Advicenne Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Hege Hellstrom | Self | Chief Commercial Officer | 000 0000 |
| Jean-Pierre Lefoulon | Self | Board Member | 000 0000 |
| Philippe Boucheron | Bpifrance | Chairman & Board Member | 000 0000 |
| Thibaut Roulon Ph.D | Bpifrance | Board Member | 000 0000 |
Advicenne Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Advicenne ESG
Risk Overview
Risk Rating
Updated July, 28, 2023
41.08 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,491
Rank
Percentile
Pharmaceuticals
Industry
00 of 871
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 415
Rank
Percentile
